Get the Stockscreener App
702.75
3.11%
-22.59
Pre-market:
725.16
22.41
+3.19%
Regeneron Pharmaceuticals Inc stock is traded at $702.75, with a volume of 1.37M.
It is down -3.11% in the last 24 hours and up +21.57% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$725.34
Open:
$727.81
24h Volume:
1.37M
Relative Volume:
1.29
Market Cap:
$73.21B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
16.82
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+3.08%
1M Performance:
+21.57%
6M Performance:
+17.80%
1Y Performance:
-5.62%
1-Day Range:
$702.63
$727.81
1-Week Range:
$679.93
$727.97
52-Week Range:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.76 | 61.08B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Stocks to Watch : Nvidia, Kulicke & Soffa, Regeneron - MarketScreener
Regeneron (REGN) Gains FDA Approval for Eylea HD Injection - GuruFocus
Regeneron Gets FDA Approval for Eylea to Treat Macular Edema - MarketScreener
FDA Approves Eylea HD Injection from Regeneron (REGN) for Eye Conditions - GuruFocus
FDA approves EYLEA HD for retinal vein occlusion with extended dosing - Investing.com Canada
Regeneron stock rises as EYLEA HD gets FDA approval for new indication - Investing.com Canada
Regeneron Announces FDA Approval of EYLEA HD® for Retinal Vein Occlusion with New Dosing Options - Quiver Quantitative
Regeneron (NASDAQ: REGN) secures FDA approval for EYLEA HD in RVO with 8-week option and monthly dosing - Stock Titan
Why analysts raise outlook for Regeneron Pharmaceuticals Inc. (RGO) stockJuly 2025 Highlights & Free Real-Time Market Sentiment Alerts - newser.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
Why Regeneron Pharmaceuticals Inc. (RGO) stock is favored by hedge funds2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
How currency fluctuations impact Regeneron Pharmaceuticals Inc. stockMarket Volume Summary & Reliable Momentum Entry Alerts - newser.com
Regeneron (REGN) Gains EU Approval for Expanded Use of Libtayo - GuruFocus
Regeneron gets EU nod for expanded approval of Libtayo (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals Gets European Commission's Approval for Expanded Indication for Libtayo - MarketScreener
European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc - MarketScreener
Can a trend reversal in Regeneron Pharmaceuticals Inc. lead to recoveryWeekly Investment Summary & Low Volatility Stock Recommendations - newser.com
REGN: European Approval for Regeneron's Libtayo in Skin Cancer T - GuruFocus
Regeneron (REGN) EC Approves Libtayo as First Adjuvant CSCC Immunotherapy, 68% Risk Cut - Stock Titan
How Regeneron Pharmaceuticals Inc. stock responds to policy changes2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
United States Bispecific T-cell Engagers (BiTEs) Market Size, - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Raiffeisen Bank International AG - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by ARS Investment Partners LLC - MarketBeat
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsMarket Weekly Review & Weekly High Return Forecasts - newser.com
How strong is Regeneron Pharmaceuticals Inc. stock balance sheetWeekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Can Regeneron Pharmaceuticals Inc. stock weather global recessionStop Loss & Growth Focused Investment Plans - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Citigroup Inc. - MarketBeat
Feds Look to 'False Certification' FCA Strategy - Law360
Semanteon Capital Management LP Sells 1,123 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Regeneron’s FDA Approvals and Recent Price Jump Impact Its 2025 Valuation - simplywall.st
Universal Beteiligungs und Servicegesellschaft mbH Has $55.94 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ex-Dividend Reminder: CenterPoint Energy, Regeneron Pharmaceuticals and LeMaitre Vascular - Nasdaq
SG Americas Securities LLC Has $8.42 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What data driven models say about Regeneron Pharmaceuticals Inc.’s futureJuly 2025 Sector Moves & Fast Entry and Exit Trade Plans - newser.com
PNC Financial Services Group Inc. Cuts Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bedell Frazier Investment Counselling LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Drug-maker Regeneron plans $2B facility upstate, following Trump’s pharma tariffs - Crain's New York Business
Citizens Financial Group Inc. RI Acquires 1,871 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds? - Finviz
How robust is Regeneron Pharmaceuticals Inc. (RGO) stock financial positionWeekly Trend Summary & Weekly Breakout Watchlists - newser.com
REGN: Eylea HD growth, label updates, and strategic capital deployment drive future outlook - TradingView
Chronic Obstructive Pulmonary Disease Market Forecast - openPR.com
Regeneron at Jefferies London: Strategic Growth and Challenges - Investing.com
Regeneron at Wolfe Research Conference: Oncology Pipeline Insights - Investing.com
Westwood Holdings Group Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Persistent Asset Partners Ltd Sells 5,625 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):